Zeria Pharmaceutical Co., Ltd.

TSE:4559 Stock Report

Market Cap: JP¥106.1b

Zeria Pharmaceutical Future Growth

Future criteria checks 3/6

Zeria Pharmaceutical is forecast to grow earnings and revenue by 11.1% and 7.5% per annum respectively. EPS is expected to grow by 11.1% per annum. Return on equity is forecast to be 10.9% in 3 years.

Key information

11.1%

Earnings growth rate

11.1%

EPS growth rate

Pharmaceuticals earnings growth11.1%
Revenue growth rate7.5%
Future return on equity10.9%
Analyst coverage

Low

Last updated10 Jul 2024

Recent future growth updates

Recent updates

Zeria Pharmaceutical (TSE:4559) Is Due To Pay A Dividend Of ¥23.00

Dec 17
Zeria Pharmaceutical (TSE:4559) Is Due To Pay A Dividend Of ¥23.00

Zeria Pharmaceutical (TSE:4559) Will Pay A Dividend Of ¥23.00

Dec 03
Zeria Pharmaceutical (TSE:4559) Will Pay A Dividend Of ¥23.00

Zeria Pharmaceutical's (TSE:4559) Earnings Are Of Questionable Quality

May 21
Zeria Pharmaceutical's (TSE:4559) Earnings Are Of Questionable Quality

Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥22.00

Mar 15
Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥22.00

Earnings and Revenue Growth Forecasts

TSE:4559 - Analysts future estimates and past financials data (JPY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202797,80010,70012,45017,1501
3/31/202690,0009,20011,15015,7001
3/31/202583,5008,00010,30014,7001
9/30/202481,4698,39613,45015,914N/A
6/30/202478,8769,028N/AN/AN/A
3/31/202475,7257,7318,28512,183N/A
12/31/202374,5738,638N/AN/AN/A
9/30/202371,3497,5938,91312,789N/A
6/30/202370,3826,509N/AN/AN/A
3/31/202368,3836,19510,50013,157N/A
12/31/202266,1575,898N/AN/AN/A
9/30/202264,6385,8449,26211,171N/A
6/30/202262,2895,154N/AN/AN/A
3/31/202259,5323,9617,5308,950N/A
12/31/202158,1723,476N/AN/AN/A
9/30/202157,2393,846-5,9068,796N/A
6/30/202155,6593,553N/AN/AN/A
3/31/202155,4423,119-9,2386,894N/A
12/31/202056,4974,272N/AN/AN/A
9/30/202056,9183,0833,4636,125N/A
6/30/202058,6442,753N/AN/AN/A
3/31/202060,4262,9255,9787,251N/A
12/31/201960,9192,893N/AN/AN/A
9/30/201961,6652,4044,8075,975N/A
6/30/201961,6852,356N/AN/AN/A
3/31/201961,8313,4543,9835,500N/A
12/31/201862,1393,102N/AN/AN/A
9/30/201862,6394,3095,7997,265N/A
6/30/201863,8575,744N/AN/AN/A
3/31/201864,5684,157N/A8,821N/A
12/31/201765,4504,626N/AN/AN/A
9/30/201764,9483,666N/A6,508N/A
6/30/201764,3312,873N/AN/AN/A
3/31/201764,8493,544N/A7,238N/A
12/31/201664,4643,051N/AN/AN/A
9/30/201664,4453,903N/A9,799N/A
6/30/201664,2383,950N/AN/AN/A
3/31/201662,4753,513N/A5,694N/A
12/31/201562,2842,732N/AN/AN/A
9/30/201561,2192,058N/A4,066N/A
6/30/201561,0222,400N/AN/AN/A
3/31/201561,0122,557N/A653N/A
12/31/201461,0053,866N/AN/AN/A
9/30/201462,0234,056N/A1,213N/A
6/30/201461,3713,890N/AN/AN/A
3/31/201461,9965,277N/A6,573N/A
12/31/201359,7915,276N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4559's forecast earnings growth (11.1% per year) is above the savings rate (0.3%).

Earnings vs Market: 4559's earnings (11.1% per year) are forecast to grow faster than the JP market (7.9% per year).

High Growth Earnings: 4559's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4559's revenue (7.5% per year) is forecast to grow faster than the JP market (4.2% per year).

High Growth Revenue: 4559's revenue (7.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4559's Return on Equity is forecast to be low in 3 years time (10.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 22:47
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zeria Pharmaceutical Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Takashi AkahaneTokai Tokyo Intelligence Laboratory Co., Ltd.
Jayaprabha DhavaleVirtua Research Inc.